SEC Form 4 · accession 0001209191-17-040239
Ovid Therapeutics Inc. · OVID
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barbara Gayle Duncan
Director
Period of report
Jun 14, 2017
Accepted (ET)
Jun 15, 2017 · 5:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636651
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $13.91 | Jun 14, 2017 | A | 11,627 | A | — | Jun 13, 2027 | Common Stock | 11,627 | 11,627 | D |
Explanation of responses
- F1The option shall vest as follows: 1/36th of the shares subject to the option shall vest every month after June 14, 2017, such that the option will have vested in full on June 14, 2020, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2017 Equity Incentive Plan) on each vesting date.